NewAmsterdam Pharma Company N.V.
NAMS
$16.34
$0.311.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -56.13% | 1,177.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -56.13% | 1,177.36% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -56.13% | 1,177.36% | |||
| SG&A Expenses | 14.63% | 11.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.49% | -1.35% | |||
| Operating Income | -72.90% | 52.44% | |||
| Income Before Tax | -453.68% | 57.32% | |||
| Income Tax Expenses | 100.00% | -- | |||
| Earnings from Continuing Operations | -453.72% | 57.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -453.72% | 57.32% | |||
| EBIT | -72.90% | 52.44% | |||
| EBITDA | -72.88% | 52.48% | |||
| EPS Basic | -427.60% | 57.34% | |||
| Normalized Basic EPS | -411.46% | 67.42% | |||
| EPS Diluted | -427.60% | 57.34% | |||
| Normalized Diluted EPS | -411.46% | 67.42% | |||
| Average Basic Shares Outstanding | 4.94% | 0.04% | |||
| Average Diluted Shares Outstanding | 4.94% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||